Essai Clinique Généré Le 26 Sept

Essai Clinique Généré le 26 sept. 2021 à partir de Titre A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Simplify 1) Protocole ID GS-US-352-0101 (McG 1404) ClinicalTrials.gov ID NCT01969838 Type(s) de cancer NMP : Vaquez , Thrombocythémie essentielle, Métaplasie myéloide Phase Phase III Médicament Momelotinib vs Ruxolitinib Institution HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS 3755 rue de la Côte Ste. Catherine, Montréal, QC, H3T 1E2 (Étude du programme d'oncologie de McGill) Ville Montréal Investigateur principal Dre Shireen Sirhan Coordonnateur Aline Mamo 514-340-8222 poste 5525 Statut Fermé But étude This study is to determine the efficacy of momelotinib (MMB) versus ruxolitinib in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (post-PV/ET MF) who have not yet received treatment with a Janus kinase inhibitor (JAK inhibitor). Participants will be randomized to receive either MMB or ruxolitinib for 24 weeks during a double-blind treatment phase, after which they will be eligible to receive open-label MMB for up to an additional 168 weeks. After discontinuation of study medication, assessments will continue for 12 additional weeks, after which participants will be contacted for survival follow-up approximately every 6 months for up to 5 years from the date of enrollment. Critères d'éligibilité Palpable splenomegaly at least 5 cm below the left costal margin Confirmed diagnosis of PMF or post-PV/ET MF Requires myelofibrosis therapy, in the opinion of the investigator Classified as high risk OR intermediate-2 risk as defined by the International Prognostic Scoring System (IPSS) for PMF, or intermediate-1 risk (IPSS) associated with symptomatic splenomegaly, hepatomegaly, anemia (hemoglobin < 10.0 g/dL), and/or unresponsive to available therapy Acceptable laboratory assessment obtained within 14 days prior to the first dose of study drug: Absolute neutrophil count (ANC) ≥ 0.75 x 10^9/L in the absence of growth factor in the prior 7 days Platelet Count ≥ 50 x 10^9/L (≥ 100 x 10^9/L if aspartate aminotransferase [AST] or alanine aminotransferase [ALT] is ≥ 2 x the upper limit of the normal range [ULN]) in the absence of platelet transfusion(s) or thrombopoietin mimetics in the prior 7 days Peripheral blood blast count < 10% AST and ALT ≤ 3 x ULN (≤ 5 x ULN if liver is involved by extramedullary hematopoiesis as judged by the investigator or if related to iron chelator therapy that was started within the prior 60 days) Calculated creatinine clearance (CrCL) of ≥ 45 mL/min Direct bilirubin ≤ 2.0 x ULN Life expectancy of > 24 weeks Males and females of childbearing potential must agree to use protocol-specified method(s) of contraception Females who are nursing must agree to discontinue nursing before the first dose of study drug Able to understand and willing to sign the informed consent form Critères d'exclusion Prior splenectomy Splenic irradiation within 3 months prior to the first dose of study drug Eligible for allogeneic bone marrow or stem cell transplantation Uncontrolled inter-current illness, per protocol. Known positive status for human immunodeficiency virus (HIV) Chronic active or acute viral hepatitis A, B, or C infection, or a hepatitis B or C carrier Prior use of a JAK1 or JAK2 inhibitor Use of chemotherapy, immunomodulating therapy, biologic therapy, radiation therapy, or investigational therapy within 4 weeks of the first dose of study drug Presence of peripheral neuropathy ≥ Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 Unwilling or unable to undergo a magnetic resonance imaging (MRI) or computed tomography (CT) scan.

Load more